Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation:

Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn’s disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780.

Highlights from this Publication

“In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who are likely to remain in remission and those who are likely to flare”.

BÜHLMANN fCAL® ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US.

Health Canada License: 80726

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone